{"id":496253,"date":"2021-05-20T07:04:45","date_gmt":"2021-05-20T11:04:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/"},"modified":"2021-05-20T07:04:45","modified_gmt":"2021-05-20T11:04:45","slug":"ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/","title":{"rendered":"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences"},"content":{"rendered":"
\n

LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies Virtual Healthcare Conference, taking place May 24-26, 2021 and June 1-4, 2021, respectively.<\/p>\n

During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA will discuss the Company\u2019s corporate strategy and precision medicine approach, while highlighting its clinical-stage Alzheimer\u2019s disease vaccine programs targeting phospho-Tau and Abeta. Details of the upcoming presentations are shown below.<\/p>\n

\n UBS Global Healthcare Virtual Conference<\/strong>
\n
Date: May 26, 2021 | 7:00 \u2013 7:45 am ET \/ 1:00 \u2013 1:45 pm CET
Format: Corporate presentation<\/p>\n

\n Jefferies Virtual Healthcare Conference<\/strong>
\n
Date: June 2, 2021 | 8:00 \u2013 8:25 am ET \/ 2:00 \u2013 2:25 pm CET
Format: Fireside chat<\/p>\n

A webcast of the corporate presentation and fireside chat will be available on the\u00a0Events Page<\/a>\u00a0of AC Immune\u2019s website.<\/p>\n

\n About AC Immune SA <\/strong>
\n
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigenTM<\/sup>\u00a0and MorphomerTM<\/sup>, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.<\/p>\n

\n For further information, please contact:<\/strong>\n <\/p>\n\n\n\n
\n Head of Investor Relations and <\/strong>
\n
\n Corporate Communications<\/strong>
\n
Joshua Drumm, Ph.D.
AC Immune
Phone\u00a0: +1 917 809 0814
Email: joshua.drumm@acimmune.com<\/a><\/td>\n		\n U.S. Media<\/strong>
\n
Katie Gallagher
LaVoie Health Science
Phone: +1 617 792 3937
Email: kgallagher@lavoiehealthscience.com<\/a><\/p>\n<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n European Investors & Media<\/strong>
\n
Chris Maggos
LifeSci Advisors
Phone\u00a0: +41 79 367 6254
Email\u00a0: chris@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<\/table>\n

\n Forward-looking statements<\/strong>
\n
This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies Virtual Healthcare Conference, taking place May 24-26, 2021 and June 1-4, 2021, respectively. During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA will discuss the Company\u2019s corporate strategy and precision medicine approach, while highlighting its clinical-stage Alzheimer\u2019s disease vaccine programs targeting phospho-Tau and Abeta. Details of the upcoming presentations are shown below. UBS Global Healthcare Virtual Conference Date: May 26, 2021 | 7:00 \u2013 7:45 am ET \/ 1:00 \u2013 1:45 pm CETFormat: Corporate presentation Jefferies Virtual Healthcare Conference Date: … <\/p>\n

Continue reading “AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-496253","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies Virtual Healthcare Conference, taking place May 24-26, 2021 and June 1-4, 2021, respectively. During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA will discuss the Company\u2019s corporate strategy and precision medicine approach, while highlighting its clinical-stage Alzheimer\u2019s disease vaccine programs targeting phospho-Tau and Abeta. Details of the upcoming presentations are shown below. UBS Global Healthcare Virtual Conference Date: May 26, 2021 | 7:00 \u2013 7:45 am ET \/ 1:00 \u2013 1:45 pm CETFormat: Corporate presentation Jefferies Virtual Healthcare Conference Date: … Continue reading "AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-20T11:04:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzOTg3MCM0MTkzMjQ2IzUwMDA2NDA0MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences\",\"datePublished\":\"2021-05-20T11:04:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/\"},\"wordCount\":557,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzOTg3MCM0MTkzMjQ2IzUwMDA2NDA0MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/\",\"name\":\"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzOTg3MCM0MTkzMjQ2IzUwMDA2NDA0MQ==\",\"datePublished\":\"2021-05-20T11:04:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzOTg3MCM0MTkzMjQ2IzUwMDA2NDA0MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzOTg3MCM0MTkzMjQ2IzUwMDA2NDA0MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences - Market Newsdesk","og_description":"LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) — AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies Virtual Healthcare Conference, taking place May 24-26, 2021 and June 1-4, 2021, respectively. During the conferences, Prof. Andrea Pfeifer, CEO, AC Immune SA will discuss the Company\u2019s corporate strategy and precision medicine approach, while highlighting its clinical-stage Alzheimer\u2019s disease vaccine programs targeting phospho-Tau and Abeta. Details of the upcoming presentations are shown below. UBS Global Healthcare Virtual Conference Date: May 26, 2021 | 7:00 \u2013 7:45 am ET \/ 1:00 \u2013 1:45 pm CETFormat: Corporate presentation Jefferies Virtual Healthcare Conference Date: … Continue reading \"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-20T11:04:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzOTg3MCM0MTkzMjQ2IzUwMDA2NDA0MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences","datePublished":"2021-05-20T11:04:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/"},"wordCount":557,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzOTg3MCM0MTkzMjQ2IzUwMDA2NDA0MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/","name":"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzOTg3MCM0MTkzMjQ2IzUwMDA2NDA0MQ==","datePublished":"2021-05-20T11:04:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzOTg3MCM0MTkzMjQ2IzUwMDA2NDA0MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzOTg3MCM0MTkzMjQ2IzUwMDA2NDA0MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune to Highlight First-in-Class Alzheimer\u2019s Disease Vaccine Programs at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/496253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=496253"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/496253\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=496253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=496253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=496253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}